The investigational therapy, ifinatamab deruxtecan, is a potential first-in-class B7-H3 directed DXd antibody drug conjugate discovered by Daiichi Sankyo and jointly developed with Merck
New Yamuna Vihar facility to train 40 students annually through diploma-led, hands-on renal care education
Exclusive distribution pact with Amcor broadens access to Parafilm M sealing solutions for laboratories, horticulture and industrial users
Strong limited rollout adoption across major hospital networks positions company for accelerated scale-up in interventional radiology
Three-year CSR partnership to scale community-led mental healthcare access across Chhindwara district
Strategic expansion strengthens CDMO’s support for biotech and pharma innovators across the Asia-Pacific region
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The launch saw the presence of senior clinicians and leadership from the Manipal Hospitals network
The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies
Scientists at the forum warned of an increasingly volatile health landscape
Subscribe To Our Newsletter & Stay Updated
